NCT06754267 is a Phase 2 clinical trial of Venetoclax in Precursor B-Cell Acute Lymphoblastic Leukemia, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT06754267?

NCT06754267 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT06754267?

Interventions in NCT06754267: Venetoclax, Olverembatinib, Predinisone.

What condition does NCT06754267 study?

NCT06754267 studies Precursor B-Cell Acute Lymphoblastic Leukemia.

Is NCT06754267 still recruiting?

NCT06754267 is currently recruiting now. Last updated 23 December 2024.

Last reviewed 2024-12-23 · How we verify

NCT06754267

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph-positive Precursor B Cell Acute Lymphoblastic Leukemia: a Phase II, Single Arm and Multicenter Study

Recruiting now Phase 2 Last updated 23 December 2024

What this trial tests

Phase 2 trial testing Venetoclax in Precursor B-Cell Acute Lymphoblastic Leukemia in 36 participants. Currently enrolling.

Timeline

1 December 2024

Primary endpoint
30 December 2025

30 December 2027

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 December 2024
Primary completion	30 December 2025
Estimated completion	30 December 2027
Sites	1 location across China

Drugs / interventions tested

Venetoclax (venetoclax) — full drug profile →
Olverembatinib — full drug profile →
Predinisone — full drug profile →

Conditions studied

Precursor B-Cell Acute Lymphoblastic Leukemia — all drugs for Precursor B-Cell Acute Lymphoblastic Leukemia →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

18 and older, any sex, with Precursor B-Cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

complete molecular response (CMR) after three cycles
Time frame: At the end of Cycle 3（each cycle is 28 days）
BCR::ABL1≤0.01% detected by RT-qPCR

Sponsor's own description

Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Philadelphia chromosome positive (Ph+) ALL is defined as ALL with translocation between chromosomes 9 and 22. And t(9;22)(q34;q11) is the most common chromosomal abnormality in ALL. Before the emergence of TKI, the prognosis of Ph+ ALL was extremely poor, and the long-term survival rate was only 10%-35%. Ph+ ALL accounts for about 30% of adult ALL. In this study, the investigators propose a treatment approach that combines Venetoclax with Olverembatinib and Predinisone in Ph+ B-ALL adults. The study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax.
Hanbali A, Kotb A, Saleh M. · · 2025 · cited 1× · PMID 40904937 · DOI 10.14740/jh2092
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.
Sadati S, Yazdizadeh S, Razavi SM, Homayoonfal M, et al · · 2026 · PMID 41547674 · DOI 10.1007/s12672-026-04438-x
The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review.
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M. · · 2026 · PMID 41523908 · DOI 10.1177/17588359251403912

Verify or expand the search:

Other trials of Venetoclax

Trials testing the same drug.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting

Other recruiting trials for Precursor B-Cell Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT06742515 — Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL · Phase 2 · recruiting
NCT04629729 — FT819 in Subjects With B-cell Malignancies · Phase 1 · active not recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06754267 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 23 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06754267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing